MSD and Julphar team up to address patients' needs in the region

2014-04-09

MSD, the global healthcare company known as Merck and Co within the US, and Julphar, a UAE-based pharmaceutical company, today signed a landmark five-year licensing agreement. 

The agreement provides Julphar with exclusive rights to produce, market, distribute and sell certain MSD medicines in the UAE, Kuwait, Bahrain, Oman, Qatar and Iraq.

The new partnership contributes to the ambitious healthcare plans of regional governments to improve the quality of their healthcare systems and benefit their citizens. It will potentially enhance patients' access to cutting-edge therapies for diabetes, asthma, allergy, pain and inflammation. Both companies will seek the relevant authorities' prior approvals on registration and production of the products locally. This new agreement signals the importance of the U.A.E. and the region to MSD and Julphar, and reflects their commitment to enhance patient access in a region where diabetes, asthma and other diseases pose serious healthcare challenges. 

"I am proud to announce this landmark agreement between MSD and Julphar – a partnership which will lead to having some MSD products being manufactured in this region for the very first time," said Ramsey Morad, Vice president, MSD for the Middle East region. 

"Julphar is delighted to be partnering with MSD", Dr. Ayman Sahli, Chief Executive Officer, Julphar, stated. "This partnership is the result of shared values and principles to advance healthcare in the MENA region, as we both strive for the highest standards of quality and, most importantly, focus on the welfare of patients in our communities."

Merck and MSD operate in more than 140 countries and spend more than USD 8 billion each year on medicine research and development, making it one of the largest contributors to medical research and development among global biopharmaceutical companies.

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.